{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:42:22Z","timestamp":1785426142168,"version":"3.56.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Netanasvir Phosphate is a novel second-generation NS5A inhibitor used for the treatment of chronic hepatitis C virus (HCV) infection. This study investigated the absorption, distribution, metabolism, and excretion (ADME), and the metabolite profile of [\u00b9\u2074C]Netanasvir Phosphate. In a single-dose, open-label study, six healthy Chinese male volunteers received an oral dose of 100 mg\/200 \u00b5Ci of [\u00b9\u2074C]Netanasvir Phosphate under fed conditions. Blood, urine, and fecal samples were collected for up to 336 h post-dose. Total radioactivity was measured using oxidative combustion and liquid scintillation counting, and the parent drug and its metabolites were analyzed by validated liquid chromatography\u2013tandem mass spectrometry and low-energy radiometric detection and mass spectrometry methods. The pharmacokinetic profile showed a median\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      of 5.5 h and a mean terminal half-life of 30.6 \u00b1 8.52 h. The average total recovery of radioactivity was 97.73% \u00b1 1.90%, with feces accounting for 97.71% of the administered dose and urine only 0.02%, indicating that fecal excretion is the primary elimination pathway. The parent drug was the predominant circulating and excreted component, representing 93.89% of plasma radioactivity and 78.78% of the administered dose in feces. Only minor metabolites were detected, including demethylated and oxidized derivatives. The drug was well tolerated, with no serious adverse events (SAEs) or dose-limiting toxicities observed. This mass balance and metabolite profiling study provides essential evidence supporting the favorable pharmacokinetic characteristics and metabolic stability of [\u00b9\u2074C]Netanasvir Phosphate and offers a scientific foundation for further clinical development in HCV-infected populations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01655-25","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:00:21Z","timestamp":1776679221000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Mass balance study of [\n                    <sup>14<\/sup>\n                    C]Netanasvir Phosphate in healthy Chinese participants"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3617-5983","authenticated-orcid":false,"given":"Chun-yang","family":"Zhao","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang-yi","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-lei","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ming","family":"Xie","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Sunshine Lake Pharma Co., Ltd.","place":["Guangdong, China"]},{"name":"Enterprise Key Laboratory of Anti-viral Drug Development","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-3219","authenticated-orcid":true,"given":"Jing-ying","family":"Jia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-8447","authenticated-orcid":true,"given":"Yan-mei","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"publisher"}],"name":"Drug Clinical Trial Center, Shanghai Xuhui Central Hospital\/Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Organization WH. 2016. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection updated version April 2016: guidelines. World Health Organization"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i41.6957"},{"key":"e_1_3_3_4_2","first-page":"31","article-title":"Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma","volume":"51","author":"Leone N","year":"2005","unstructured":"Leone N, Rizzetto M. 2005. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51:31\u201346.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2007.01419.x"},{"key":"e_1_3_3_6_2","unstructured":"Buchanan R Medicine N. 2019. Hepatitis C. Medicine (Baltimore) [Internet]. Available from: https:\/\/consensus.app\/papers\/hepatitis-c-buchanan-nash\/03c53df156f25ce2a73c6fba56d4ca5c\/"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.21037\/amj.2017.05.10"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02352-08"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx300050f"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0051-z"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/js970486q"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.067496"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.01.033"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.03.009"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0397-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02084-16"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0654-5"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1014"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2017-0007"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0645-6"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13254"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01655-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01655-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:03:25Z","timestamp":1781787805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01655-25"}},"subtitle":[],"editor":[{"given":"Zhaohui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1128\/aac.01655-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01655-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"2025-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01655-25"}}